Popular Stories
- Arcutis Biotherapeutics (N
- Nexgel: Bringing Innovatio
- Ekso Bionics: Advancing Ra
- Esperion: Revolutionizing
- AMSC: Restructuring the Po
- Harrow Inc: Envisioning a
SAMPLE REPORTS
- Company Summary.pdf
- Daily Market Updates.pdf
- Initiating Coverage.pdf
- Investors' Presentation.pdf
- Portfolio Performance Analysis.pdf
- Pre-Result Analysis.pdf
- Result Review.pdf
- Short Initiating Coverage.pdf

Madrigal Pharmaceuticals linkedin Tag

  • All
  • Beauty
  • Biotechnology
  • Cannabis
  • Communications
  • Education
  • Energy
  • Entertainment
  • Environment
  • ETFs
  • Finance
  • Fitness
  • Food and Beverage
  • Healthcare
  • Hospitality
  • Insider Trading
  • Investing Ideas
  • Macro
  • Market Insight
  • Miscellaneous
  • Power
  • Real Estate
  • Retail
  • Sectors
  • Security
  • Startups
  • Technologies
  • Trending
  • Uncategorized
Can Intercept Make it to the Finishing Line in NASH?
Can Intercept Make it to the Finishing Line in NASH?

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) is a biopharmaceutical Company aiming to create novel therapeutics for the treatment of progressive non-viral liver diseases. The Company’s lead compound Ocalive or obeticholic acid (OCA), is an analog of the bile acid chenodeoxycholic acid (CDCA), which is being evaluated for...

11 February, 2022 0 Comments
Will Resmetirom Prove to be a Gamechanger in NASH?
Will Resmetirom Prove to be a Gamechanger in NASH?

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company, is developing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, an approach that has the potential to address the unmet needs in cardiovascular, metabolic and fatty liver diseases. The Company’s research is...

04 February, 2022 0 Comments
WordPress Video Lightbox Plugin